CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. With a market capitalization of $1.36B, it sits in small-cap territory. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Market Cap
$1.36B
Beta
0.93
P/E (TTM)
24.20
P/E (Fwd)
9.53
EPS (TTM)
$1.86
EPS (Fwd)
$4.72
ROE
5.5%
ROA
3.8%
Cash
$35.0M
Total Debt
$860.9M
Free CF
$127.1M
52W Change
-8.6%
Annual Financials
Cash vs Debt
The company holds $35.0M in cash, though total debt stands at $860.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $127.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 5.5%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.05B (2022) to $1.37B (2025), reflecting a 31% increase over the period.
CONMED Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence CONMED Corporation's trajectory.